Ann Surg Treat Res.  2014 Sep;87(3):118-122. 10.4174/astr.2014.87.3.118.

Clinical application of sentinel lymph node mapping in colon cancer: in vivo vs. ex vivo techniques

• Oh SY
• Kim DY
• Kim YB
• Suh KW

• KMID: 1908481
• DOI: http://doi.org/10.4174/astr.2014.87.3.118

Abstract

PURPOSE
Clinical usefulness of sentinel lymph node (SLN) mapping in colorectal cancer remains controversial. The aim of this study is to evaluate the accuracy of the SLN mapping technique using serial sectioning, and to compare the results between ex vivo and in vivo techniques.
METHODS
From February 2011 to October 2012, 34 colon cancer patients underwent SLN mapping during surgical resection. Eleven patients were analyzed with the in vivo method, and 23 patients with the ex vivo method. Patient characteristics and results of SLN mapping were evaluated.
RESULTS
The SLN mapping was performed in 34 patients. Mean age was 67.3 years (range, 44-81 years). Primary tumors were located in the following sites: 13 in the right colon (38.2%) and 21 in the left colon (61.8%). SLN mapping was performed successfully in 88.2% of the patients. There was no significant difference in the identification rate between the two methods (90.9% vs. 87.0%, P = 1.000). Both the mapping methods showed a low sensitivity and high rate of skip metastasis.
CONCLUSION
This study showed that SLN evaluation using serial sectioning could not predict the nodal status with clinically acceptable accuracy despite the high detection rate.

Keyword

Sentinel lymph node biopsy; Colon neoplasms

MeSH Terms

Colon
Colonic Neoplasms*
Colorectal Neoplasms
Humans
Lymph Nodes*
Neoplasm Metastasis
Sentinel Lymph Node Biopsy

Reference

1. Cohen AM, Kelsen D, Saltz L, Minsky BD, Nelson H, Farouk R, et al. Adjuvant therapy for colorectal cancer. Curr Probl Surg. 1997; 34:601–676.

2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56:106–130.

3. André T, Afchain P, Barrier A, Blanchard P, Larsen AK, Tournigand C, et al. Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res. 2007; 1:90–97.

4. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B, Hardcastle JD, et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol. 1991; 6:325–344.

5. Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg. 2006; 244:602–610.

6. Choi HK, Law WL, Poon JT. The optimal number of lymph nodes examined in stage II colorectal cancer and its impact of on outcomes. BMC Cancer. 2010; 10:267.

7. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992; 127:392–399.

8. Yasuda K, Adachi Y, Shiraishi N, Yamaguchi K, Hirabayashi Y, Kitano S. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2001; 8:300–304.

9. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998; 339:223–228.

10. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review. J Surg Oncol. 1998; 67:194–202.

11. Bembenek A, Schneider U, Gretschel S, Fischer J, Schlag PM. Detection of lymph node micrometastases and isolated tumor cells in sentinel and nonsentinel lymph nodes of colon cancer patients. World J Surg. 2005; 29:1172–1175.

12. Dahl K, Westlin J, Kraaz W, Winqvist O, Bergkvist L, Thorn M. Identification of sentinel nodes in patients with colon cancer. Eur J Surg Oncol. 2005; 31:381–385.

13. Bertagnolli M, Miedema B, Redston M, Dowell J, Niedzwiecki D, Fleshman J, et al. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg. 2004; 240:624–628.

14. Tuech JJ, Pessaux P, Di Fiore F, Nitu V, Lefebure B, Colson A, et al. Sentinel node mapping in colon carcinoma: in-vivo versus ex-vivo approach. Eur J Surg Oncol. 2006; 32:158–161.

15. Park JS, Chang IT, Park SJ, Kim BG, Choi YS, Cha SJ, et al. Comparison of ex vivo and in vivo injection of blue dye in sentinel lymph node mapping for colorectal cancer. World J Surg. 2009; 33:539–546.

16. Vîlcea ID, Vasile I, Mirea CS, Meşina C, Enache SD, Tenovici M, et al. Sentinel lymph node study in colorectal cancer using serial sectioning and Hematoxylin-Eosin staining: importance and limitations. Rom J Morphol Embryol. 2011; 52:1 Suppl. 379–383.

17. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005; 97:219–225.

18. Bamboat ZM, Deperalta D, Dursun A, Berger DL, Bordeianou L. Factors affecting lymph node yield from patients undergoing colectomy for cancer. Int J Colorectal Dis. 2011; 26:1163–1168.

19. Caplin S, Cerottini JP, Bosman FT, Constanda MT, Givel JC. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer. 1998; 83:666–672.

20. Saha S, Johnston G, Korant A, Shaik M, Kanaan M, Johnston R, et al. Aberrant drainage of sentinel lymph nodes in colon cancer and its impact on staging and extent of operation. Am J Surg. 2013; 205:302–305.

21. Wong JH, Johnson DS, Hemmings D, Hsu A, Imai T, Tominaga GT. Assessing the quality of colorectal cancer staging: documenting the process in improving the staging of node-negative colorectal cancer. Arch Surg. 2005; 140:881–886.

22. Cahill RA. What's wrong with sentinel node mapping in colon cancer? World J Gastroenterol. 2007; 13:6291–6294.

23. Lim SJ, Feig BW, Wang H, Hunt KK, Rodriguez-Bigas MA, Skibber JM, et al. Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. Ann Surg Oncol. 2008; 15:46–51.

24. Viehl CT, Hamel CT, Marti WR, Guller U, Eisner L, Stammberger U, et al. Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size. World J Surg. 2003; 27:1285–1290.

25. Feig BW, Curley S, Lucci A, Hunt KK, Vauthey JN, Mansfield PF, et al. A caution regarding lymphatic mapping in patients with colon cancer. Am J Surg. 2001; 182:707–712.

26. Paramo JC, Summerall J, Poppiti R, Mesko TW. Validation of sentinel node mapping in patients with colon cancer. Ann Surg Oncol. 2002; 9:550–554.

27. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353:2654–2666.

28. Chou JF, Row D, Gonen M, Liu YH, Schrag D, Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer. 2010; 116:2560–2570.